+91 80 2808 2808

Biocon Facility Completes Pre Approval U.S. FDA Inspection

  • Posted by: BIOCON


Company Statement

Bengaluru, India, Mar 06, 2019

“This is to inform you that the U.S. FDA concluded a pre-approval inspection of Biocon’s insulin drug substance manufacturing facility triggered by a New Drug Application submitted by our insulin API customer.

The inspection at the Bengaluru facility took place between 25th Feb – 5th Mar, 2019, resulting in a Form 483 with six observations.

Biocon is confident of addressing these expeditiously and remains committed to global standards of Quality and Compliance”

– Company Spokesperson

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>